Denosumab Market Growth Fueled By Rising Osteoporosis Prevalence: Strategic Insights Driving Denosumab Market Momentum in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Denosumab Market Size By 2025?
The market for denosumab has seen significant expansion in recent times. The growth is expected to rise from $3.27 billion in 2024 to $3.67 billion in 2025, portraying a compound annual growth rate (CAGR) of 12.1%. The increase during the historic period can be accredited to factors like advancements in clinical trials and research, FDA approvals and regulatory milestones, heightened awareness about bone health, along with strategic collaborations and marketing efforts.

How Big Is the Denosumab Market Size Expected to Grow by 2029?
The market size of denosumab is predicted to experience a significant increase in the upcoming years, expanding to "$5.48 billion in 2029 with a 10.6% compound annual growth rate (CAGR). The expected growth during the forecast timeframe can be due to factors such as an increasing occurrence of bone metastases, improved cancer treatments, prevalence of osteoporosis, heightened awareness about osteoporosis, and the approval of regulations for new indications. Notable trends during the forecast period could involve strategic alliances and associations, digital health solutions integration, broadened indications and clinical uses, and enhancements in the development of biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/denosumab-global-market-report

Which Key Market Drivers Powering Denosumab Market Expansion and Growth?
The denosumab market is projected to grow as osteoporosis becomes more common. Osteoporosis is a health issue characterized by weakened bones, leading to a decrease in bone density and increased risk of fractures. Denosumab helps counteract osteoporosis by halting bone resorption through the RANK ligand's targeting. For example, The National Center for Biotechnology Information, a U.S. government agency, reported in September 2023 that data from the Canadian Longitudinal Study on Aging indicated a 12.7% prevalence of osteoporosis diagnosed by physicians and a 5.9% occurrence of DXA-confirmed osteoporosis among older, community-dwelling females. Furthermore, Buttros and associates completed a cross-sectional research revealing a 24.6% incidence of osteoporosis in postmenopausal women aged 40 to 75, identified via bone mineral density (BMD) measurements. As such, the escalating incidence of osteoporosis is fueling denosumab market growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13835&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Denosumab Market?
Firms with major presence in the denosumab market are focusing more on creating innovative solutions, such as primary treatment options for osteoporosis, in order to maintain a competitive advantage. Initial treatments for osteoporosis are the main therapeutic strategies suggested by healthcare professionals for patients diagnosed with the condition. For example, in November 2022, China's Boan Biotech, a biotech firm, secured approval from the National Medical Products Administration (NMPA) in China for its denosumab biosimilar, Boyoubei, becoming the first company in China to do so. The firm is also working on making this injection available in markets outside China, such as Europe and the United States, with a strategy for global promotion. Various treatment guidebooks have nominated this drug as a primary treatment for osteoporosis. The drug can dramatically reduce the chances of hip, non-vertebral, and vertebral fractures among patients. Moreover, Boyoubei is the first biosimilar to Prolia (the creator of denosumab) to be approved for global marketing.

What Are the Emerging Segments in the Denosumab Market?
The denosumab market covered in this report is segmented -

1) By Drug Classification: Prolia, Xgeva, Others
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13835&type=smp

Who Are the Global Leaders in the Denosumab Market?
Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited

Which are the Top Profitable Regional Markets for the Denosumab Industry?
North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13835

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.